Clinical Data Rules for Class III Devices in Thailand

Every Class III medical device submission to Thailand's FDA carries a clinical evaluation requirement, and it is one of the most commonly underestimated parts of a CSDT dossier. Manufacturers who treat the clinical section as a formality, assembled from whatever home-market paperwork already exists, tend to be the ones who receive deficiency letters. Understanding what the Medical Devices Control Division (MDCD) actually expects in Part V of the CSDT, and when it will ask for more, changes how a submission should be built from the outset.

Where Class III Sits in Thailand's Framework

Medical devices in Thailand fall under the Medical Device Act B.E. 2551 (2008) and its amendment B.E. 2562 (2019), both administered by the MDCD under the Thai FDA. The 2562 amendment expanded the division's authority and sharpened classification criteria to align with ASEAN harmonization goals. Under the ASEAN Medical Device Directive (AMDD), Thailand's Class III corresponds to AMDD Class C: devices carrying moderate-to-high risk that are not implantable and do not fall into the highest-risk Class IV tier. Active therapeutic devices, diagnostic imaging equipment with patient contact, and devices intended for temporary circulatory-system use are typical examples.

Registration requires a Common Submission Dossier Template (CSDT), the ASEAN-harmonized format Thailand has adopted. The CSDT dictates how clinical evidence must be presented and substantiated, and it is not a flexible template. Submissions that under-invest in the clinical section are among the most frequent sources of major deficiencies at review.

Why Part V Carries So Much Weight

The CSDT has five parts. Part I covers administrative details, Part II the device description, Part III conformance with Essential Principles of Safety and Performance, and Part IV the risk management file. Part V, the Clinical Evaluation section, is where Class III submissions live or die. It must demonstrate that the device achieves its intended purpose, that benefits outweigh residual risks, and that performance claims rest on actual clinical evidence rather than general literature about a broad device category.

The distinction the MDCD draws matters: device-specific evidence, tied to the exact model, configuration, and intended use in the submission, is what anchors the clinical evaluation. Category-level literature can support that evaluation but cannot substitute for it. A submission that cites studies on a general class of devices without tying them to the specific product under review will typically come back with a request for supplementary data.

What Evidence the MDCD Will Accept

Literature-based clinical evaluation is acceptable for most Class III devices. A manufacturer can build Part V around a systematic review of peer-reviewed studies, provided the literature is specific to the device or to a device already shown to be equivalent, and provided the review documents its methodology: search strategy, quality appraisal, and conclusions tied directly to the claimed intended use.

Clinical data from other markets can support the file. A U.S. FDA 510(k) performance summary, a CE Mark clinical evaluation report, or Health Canada licence documentation can all appear in Part V as supporting evidence that other competent authorities have reviewed the device. What they cannot do is replace the structured Part V requirement itself. The MDCD reviews the clinical evaluation as a standalone document built for the Thai submission, not as a stack of foreign approval letters.

Post-market clinical follow-up (PMCF) data, particularly for devices with a multi-year track record elsewhere, strengthens a literature-based evaluation with real-world evidence. Where a manufacturer submits data from a clinical investigation, the MDCD expects it to have been conducted under ISO 14155, the international good clinical practice standard for device investigations. If it was not, the dossier needs a gap analysis explaining how the methodology used still meets an equivalent standard of rigor.

Building an Equivalence Argument When Direct Data Is Thin

When a manufacturer lacks clinical data specific to the exact device under registration, Thailand's CSDT guidance permits an equivalence argument, provided equivalence is established across three dimensions: intended purpose, biological characteristics, and technical characteristics. Intended purpose equivalence means the predicate device and the device under registration share the same clinical purpose, patient population, anatomical site, and expected outcome; a device intended for adults cannot lean on a predicate studied only in children without further justification.

Biological equivalence requires that patient-contact materials match, or that any differences are shown not to matter for safety or performance. Technical equivalence requires that physical, mechanical, and operational characteristics are comparable and that any gaps do not affect the clinical outcome. None of this can be asserted by table alone. The MDCD expects narrative reasoning explaining why identified differences between the two devices are not clinically significant, and an underdeveloped equivalence argument is one of the most common sources of deficiency queries at this review stage.

When the MDCD Will Ask for Thailand-Specific Data

Additional Thailand-specific clinical data becomes likely in three scenarios: when Thailand's disease profile or clinical setting introduces factors the original studies did not account for, when the Thai label carries a more specific indication than what the literature covers, or when the intended use has no direct precedent in the available evidence. Manufacturers should review their intended use statement before assembling Part V. A statement broader than the evidence supports invites scrutiny; one narrower than the evidence allows may needlessly limit commercial scope.

Novel technologies draw more attention. Where a device has limited clinical history, whether because of a new mechanism of action or a short track record elsewhere, the MDCD may require prospective clinical data before granting registration. A pre-submission meeting with the division is worth arranging in these cases, since it lets a manufacturer understand the evidentiary bar before committing to dossier preparation and to check whether a phased or conditional pathway is available. Class IV devices, which include active implantables and devices with central-nervous-system or cardiovascular contact, face a materially higher evidentiary threshold than Class III and often require post-market clinical study commitments as a registration condition. A manufacturer with products spanning both classes should plan the clinical evidence strategy for each separately.

Assembling the Clinical Evaluation File

A complete clinical evaluation file for a Class III CSDT submission generally has four components: a clinical evaluation plan defining the scope and appraisal criteria, a literature search report recording the databases, search terms, dates, and selection criteria used, the clinical evaluation report itself synthesizing the evidence and applying the equivalence argument where used, and a post-market surveillance plan describing how clinical data will continue to be gathered after registration.

The clinical evaluation is not a one-time deliverable. It should be updated as new post-market data, published literature, and post-registration investigation results become available, and the MDCD's inspection programme increasingly checks whether the evaluation has stayed current rather than only whether it was adequate when first filed. Dossiers built with a well-structured Part V, a documented literature search, and a coherent equivalence argument where applicable tend to move through review far more predictably than those assembled from unadapted home-market documents.

DeeMED Consulting prepares CSDT clinical evaluation files for foreign manufacturers registering Class III and Class IV devices in Thailand, including Part V structuring, equivalence argument development, and MDCD submission support. Getting the clinical section right the first time is consistently faster and cheaper than responding to a deficiency letter after the fact.